Nuvalent (NUVL)

• Market cap: $5.1B
• 1 day: -2.93%
• 5 days: 3.72%
• 1 month: 5.30%
• 3 months: -7.33%
• 6 months: -20.57%
• Year to date: -7.91%
• 1 year: 5.64%
• 5 years: 292.85%
• 10 years: 292.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Employees: 162

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

46% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $16.1M

8% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 13 (+1) [Q1 2025]

1.15% more ownership

Funds ownership: 107.56% [Q4 2024] → 108.71% (+1.15%) [Q1 2025]

8% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 72

5% less funds holding

Funds holding: 214 [Q4 2024] → 203 (-11) [Q1 2025]

8% less capital invested

Capital invested by funds: $5.52B [Q4 2024] → $5.1B (-$425M) [Q1 2025]

29% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 35

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $100 36% upside
• Avg. target: $105 43% upside
• High target: $110 49% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

UBS David Dai	36% upside $100	Buy Upgraded	14 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth	49% upside $110	Buy Reiterated	3 Mar 2025